{"id":"NCT02953314","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)","officialTitle":"A Phase 3, Open Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661 in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous or Heterozygous for the F508del CFTR Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11","primaryCompletion":"2018-09","completion":"2018-09","firstPosted":"2016-11-02","resultsPosted":"2019-12-05","lastUpdate":"2020-03-04"},"enrollment":83,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"TEZ","otherNames":["tezacaftor","VX-661"]},{"type":"DRUG","name":"TEZ/IVA","otherNames":["tezacaftor/ivacaftor","VX-661/VX-770"]},{"type":"DRUG","name":"IVA","otherNames":["ivacaftor","VX-770"]}],"arms":[{"label":"Part A","type":"EXPERIMENTAL"},{"label":"Part B","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, 2-part (Part A and Part B), open label, multicenter study evaluating the pharmacokinetic (PK), safety, and tolerability of multiple doses of tezacaftor (TEZ) in combination with ivacaftor (IVA) in subjects 6 through 11 years of age with CF who are homozygous or heterozygous for the F508del- CF transmembrane conductance regulator protein (CFTR) mutation.","primaryOutcome":{"measure":"Part A: Maximum Observed Concentration (Cmax) of TEZ and IVA","timeFrame":"Day 1 and Day 14","effectByArm":[{"arm":"Part A","deltaMin":6630,"sd":10.3}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":10},"locations":{"siteCount":33,"countries":["United States","Canada"]},"refs":{"pmids":["31253540"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Pyrexia","Nasal congestion","Abdominal pain"]}}